专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013033400A9 METHODS FOR EFFECTIVELY AND RAPIDLY DESENSITIZING ALLERGIC PATIENTS 审中-公开
公开(公告)号：WO2013033400A9
公开(公告)日：2013-03-07
申请号：PCT/US2012/053145
申请日：2012-08-30
申请人： PEROSPHERE INC. , LAULICHT, Bryan, E. , BAKHRU, Sasha, H. , STEINER, Solomon, S. , MATHIOWITZ, Edith
发明人： LAULICHT, Bryan, E. , BAKHRU, Sasha, H. , STEINER, Solomon, S. , MATHIOWITZ, Edith
IPC分类号： A61K39/35 , A61K9/50 , A61K9/48 , A61K47/30 , A61P37/00

2. 发明申请

WO2013025442A2 CONCENTRATED FELBAMATE FORMULATIONS FOR PARENTERAL ADMINISTRATION 审中-公开
标题翻译：用于肠胃外给药的浓缩的佛氨酸盐制剂
公开(公告)号：WO2013025442A2
公开(公告)日：2013-02-21
申请号：PCT/US2012/050148
申请日：2012-08-09
申请人： PEROSPHERE INC. , BAKHRU, Sasha, H. , LAULICHT, Bryan, E. , MATHIOWITZ, Edith , STEINER, Solomon, S.
发明人： BAKHRU, Sasha, H. , LAULICHT, Bryan, E. , MATHIOWITZ, Edith , STEINER, Solomon, S.
IPC分类号： A61K31/55 , A61K31/27 , A61K9/16 , A61K9/14 , A61P25/00
CPC分类号： A61K31/27 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/145 , A61K31/55 , A61K47/10 , A61K47/20
摘要： Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma.
摘要翻译：本文描述了用于肠胃外给药的神经保护剂的制剂。该制剂为浓缩（过饱和）溶液或微粒浓缩悬浮液的形式。悬浮介质或溶液溶剂载体也可含有溶解的神经保护剂。对于过饱和溶液，试剂以适合非肠道给药的溶剂中以至少约1重量％，5重量％，10重量％，15重量％或20重量％的高浓度溶解。对于浓缩悬浮液，微粒具有约100nm至约5微米，优选约50nm至约3微米，更优选约10nm至约2微米的有效粒度。本文所述的制剂可用于治疗多种神经疾病/病症和/或神经损伤或创伤。

3. 发明申请

WO2010102020A1 INSULIN FORMULATIONS FOR RAPID UPTAKE 审中-公开
标题翻译：胰岛素制剂用于快速摄取
公开(公告)号：WO2010102020A1
公开(公告)日：2010-09-10
申请号：PCT/US2010/026073
申请日：2010-03-03
申请人： BIODEL INC. , STEINER, Solomon, S. , POHL, Roderike , LI, Ming , HAUSER, Robert
发明人： STEINER, Solomon, S. , POHL, Roderike , LI, Ming , HAUSER, Robert
IPC分类号： A61K38/28 , A61K47/12 , A61K47/18 , A61K9/00
CPC分类号： A61K9/0019 , A61K38/00 , A61K38/28 , A61K47/12 , A61K47/183 , C07K14/62
摘要： Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection.
摘要翻译：本文描述了具有改善的稳定性和快速起效的可注射的胰岛素制剂。制剂可用于皮下，皮内或肌内给药。在优选的实施方案中，通过皮下注射施用制剂。制剂含有胰岛素与螯合剂和溶解剂以及任选的其它赋形剂。在优选的实施方案中，制剂含有人胰岛素，锌螯合剂如EDTA和溶解剂如柠檬酸或柠檬酸钠。当通过皮下注射给药时，这些制剂被迅速地吸收到血流中。

4. 发明申请

WO2009048959A1 RAPID ACTING INJECTABLE INSULIN COMPOSITIONS 审中-公开
标题翻译：快速注射胰岛素组合物
公开(公告)号：WO2009048959A1
公开(公告)日：2009-04-16
申请号：PCT/US2008/079213
申请日：2008-10-08
申请人： BIODEL, INC. , POHL, Roderike , STEINER, Solomon, S.
发明人： POHL, Roderike , STEINER, Solomon, S.
IPC分类号： A61P3/10 , A61K38/47 , A61K47/12
CPC分类号： A61K47/183 , A61K9/0056 , A61K38/28 , A61K47/12 , A61K2300/00
摘要： Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration, In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection, In the preferred embodiment, the insulin is provided as a dry powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration. In another embodiment, the insulin is stored as a frozen mixture, ready for use upon thawing.
摘要翻译：本文描述了具有改善的稳定性和快速起效的可注射的胰岛素制剂。制剂可用于皮下，皮内或肌肉内给药。在优选的实施方案中，制剂通过皮下注射给药。制剂含有与螯合剂和溶解剂以及任选的其它赋形剂组合的胰岛素。在优选的实施方案中，制剂含有人胰岛素，锌螯合剂如EDTA和溶解剂如柠檬酸。当通过皮下注射给药时，这些制剂被迅速地吸收到血流中。在优选的实施方案中，将胰岛素作为无菌小瓶中的干粉提供。将其与包含药学上可接受的载体如水，锌螯合剂如EDTA的稀释剂和不久之前或给药时的溶解剂如柠檬酸混合。在另一个实施方案中，将胰岛素作为冷冻混合物储存，准备在解冻时使用。

5. 发明申请

WO2012006283A1 COMPOSITIONS AND METHODS FOR MODULATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF INSULIN 审中-公开
标题翻译：调节胰岛素药物动力学和药物动力学的组合物和方法
公开(公告)号：WO2012006283A1
公开(公告)日：2012-01-12
申请号：PCT/US2011/042957
申请日：2011-07-05
申请人： BIODEL INC. , POHL, Roderike , STEINER, Solomon, S. , HAUSER, Robert , SEIBERT, Richard , LI, Ming
发明人： POHL, Roderike , STEINER, Solomon, S. , HAUSER, Robert , SEIBERT, Richard , LI, Ming
IPC分类号： A61K38/28 , C07K14/62
CPC分类号： C07K14/62 , A61K9/0019 , A61K38/28 , A61K47/183
摘要： Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of rapid acting injectable insulin formulations are described herein. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid ("EDTA") and a dissolution/stabilization agent, and optionally additional excipients. Calcium disodium EDTA is less likely to remove calcium from the body, and typically has less pain on injection in the subcutaneous tissue. Modulating the type and quantity of EDTA can change the insulin absorption profile. Increasing the quantity of citrate can further enhance absorption and chemically stabilize the formulation. In the preferred embodiment, the formulation contains human insulin, calcium disodium EDTA and a dissolution/stabilization agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection.
摘要翻译：本文描述了用于调节快速作用的可注射胰岛素制剂的药代动力学和药效学的组合物和方法。在优选的实施方案中，通过皮下注射施用制剂。制剂含有与锌螯合剂如乙二胺四乙酸（“EDTA”）和溶解/稳定剂以及任选的其它赋形剂组合的胰岛素。 EDTA二钠不太可能从体内去除钙，并且通常在皮下组织中注射时疼痛较少。调节EDTA的类型和数量可以改变胰岛素吸收特征。增加柠檬酸盐的量可以进一步增强吸收和化学稳定制剂。在优选的实施方案中，制剂含有人胰岛素，EDTA二钠钙和溶解/稳定剂如柠檬酸或柠檬酸钠。当通过皮下注射给药时，这些制剂被快速地吸收到血流中。

6. 发明申请

WO2011156476A3 INSULIN WITH A BASAL RELEASE PROFILE 审中-公开
公开(公告)号：WO2011156476A3
公开(公告)日：2011-12-15
申请号：PCT/US2011/039608
申请日：2011-06-08
申请人： BIODEL INC. , POHL, Roderike , KASHYAP, Nandini , HAUSER, Robert , OZHAN, Koray , STEINER, Solomon, S.
发明人： POHL, Roderike , KASHYAP, Nandini , HAUSER, Robert , OZHAN, Koray , STEINER, Solomon, S.
IPC分类号： A61K38/28
摘要： A basal insulin formulation composed of insulin (preferably human recombinant insulin), buffering agents, precipitating agents, and/or stabilizing agents for subcutaneous, intradermal or intramuscular administration. In one embodiment, the formulation is designed to form a precipitate of insulin following injection, creating a slow releasing "basal insulin" over a period of 12 to 24 hours. In one embodiment, the insulin formulation is prepared as a suspension for subcutaneous or intramuscular injection at neutral pH (e.g. pH 7), containing human recombinant insulin, a zinc compound, preferably zinc chloride, and a pH buffering agent, preferably sodium acetate. The suspension contains precipitated insulin particles prior to injection and provides a sustained release basal insulin profile following injection.

7. 发明申请

WO2011143421A1 INSULIN WITH A STABLE BASAL RELEASE PROFILE 审中-公开
标题翻译：胰岛素具有稳定的基本释放特征
公开(公告)号：WO2011143421A1
公开(公告)日：2011-11-17
申请号：PCT/US2011/036241
申请日：2011-05-12
申请人： BIODEL INC. , POHL, Roderike , KASHYAP, Nandini , HAUSER, Robert , OZHAN, Koray , STEINER, Solomon, S.
发明人： POHL, Roderike , KASHYAP, Nandini , HAUSER, Robert , OZHAN, Koray , STEINER, Solomon, S.
IPC分类号： A61K38/28 , A61K47/02 , A61K9/00 , A61K47/12 , A61K47/36
CPC分类号： A61K9/0021 , A61K9/0024 , A61K9/19 , A61K38/28 , A61K47/02 , A61K47/183 , A61K47/26
摘要： A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing "basal insulin" over a period of 12 to 24 hours.
摘要翻译：已经开发了用于皮下，皮内或肌肉内施用的由胰岛素，优选甘精胰岛素，可注射锌和可注射铁化合物作为沉淀和/或稳定剂的基础胰岛素制剂。该制剂被设计为在注射后形成胰岛素沉淀，在12至24小时的时间段内产生缓慢释放的“基础胰岛素”。

8. 发明申请

WO2011049713A2 STABILIZED GLUCAGON SOLUTIONS 审中-公开
标题翻译：稳定的GLUCAGON解决方案
公开(公告)号：WO2011049713A2
公开(公告)日：2011-04-28
申请号：PCT/US2010/050386
申请日：2010-09-27
申请人： BIODEL INC. , STEINER, Solomon, S. , HAUSER, Robert , LI, Ming , FELDSTEIN, Robert , POHL, Roderike
发明人： STEINER, Solomon, S. , HAUSER, Robert , LI, Ming , FELDSTEIN, Robert , POHL, Roderike
IPC分类号： A61K38/26
CPC分类号： A61K9/0019 , A61K9/1075 , A61K38/26 , A61K47/24 , A61K47/26
摘要： A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 370C.
摘要翻译：已经设计了由糖如葡萄糖和表面活性剂如肉豆蔻酰溶血磷脂酰胆碱（LMPC）组成的制剂，以在长时间的生理条件下稳定胰高血糖素分子的亲水部分和疏水部分，其浓度与pH和pH足够相似，血浆的渗透压，以免诱发或最小化部位刺激。单糖和表面活性剂的组合在37℃下使胰高血糖素分子在水溶液中稳定7天。

9. 发明申请

WO2007041481A1 RAPID ACTING AND PROLONGED ACTING INSULIN PREPARATIONS 审中-公开
标题翻译：快速作用和促进胰岛素制备
公开(公告)号：WO2007041481A1
公开(公告)日：2007-04-12
申请号：PCT/US2006/038410
申请日：2006-09-29
申请人： BIODEL, INC. , STEINER, Solomon, S. , POHL, Roderike
发明人： STEINER, Solomon, S. , POHL, Roderike
IPC分类号： A61K38/28
CPC分类号： A61K38/28 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/006 , A61K9/0075 , A61K9/0078 , A61K47/12 , A61K47/183
摘要： It has been discovered that by combining a chelator such as ethylenediaminetetraacetic acid with an acidifier such as citric acid, that the insulin is absorbed much more rapidly than in the absence of the chelator and acidifier. It has also been determined that by combining insulin with a chelator and acidifier, with a commercially available rapid, intermediate or long lasting insulin such as glargine, one can increase and/or prolong the bioavailability of the insulin mixture. The formulations are suitable for administration by injection or to a mucosal surface such as the pulmonary or oral regions, although subcutaneous injection is preferred.
摘要翻译：已经发现，通过将诸如乙二胺四乙酸的螯合剂与酸化剂如柠檬酸组合，胰岛素被吸收得比不存在螯合剂和酸化剂时快得多。还已经确定，通过将胰岛素与螯合剂和酸化剂与市售的快速，中等或长效胰岛素如甘精胰岛组合，可以增加和/或延长胰岛素混合物的生物利用度。制剂适合于通过注射施用或粘膜表面如肺部或口腔区域，尽管皮下注射是优选的。

10. 发明申请

WO2009089181A1 INSULIN FORMULATIONS FOR INSULIN RELEASE AS A FUNCTION OF TISSUE GLUCOSE LEVELS 审中-公开
标题翻译：胰岛素释放作为组织葡萄糖水平的功能的胰岛素制剂
公开(公告)号：WO2009089181A1
公开(公告)日：2009-07-16
申请号：PCT/US2009/030153
申请日：2009-01-05
申请人： BLODEL, INC. , KASHYAP, Nandini , STEINER, Solomon, S. , POHL, Roderike
发明人： KASHYAP, Nandini , STEINER, Solomon, S. , POHL, Roderike
IPC分类号： A61K47/46 , A61K38/28
CPC分类号： A61K9/0019 , A61K38/28 , A61K47/46
摘要： Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patient's tissue glucose level, which in turn maintains the patient's blood glucose level within an optimum range. The formulation is often referred to as a "smart" formulation since it modifies its release rate of insulin according to the patient's needs at a particular time. In a preferred embodiment, the formulation is designed to release insulin into the systemic circulation over time with a basal release profile following injection in a patient. In another embodiment, the formulation is designed to release insulin into the systemic circulation over time with a non-basal release profile following injection in a patient, such as a regular human insulin release profile or a prandial release profile.
摘要翻译：本文描述了能够改变基于患者组织葡萄糖水平释放的胰岛素量的可注射胰岛素制剂，制备和使用这些制剂的方法。制剂可以通过皮下，皮内或肌肉内施用来施用。在一个优选的实施方案中，通过皮下注射施用制剂。制剂含有胰岛素，氧化剂或酶，还原剂或酶，稀释剂和任选的一种或多种增稠剂。如果制剂中存在增稠剂，则增稠剂在给药后增加制剂的粘度。优选地，制剂含有胰岛素，稀释剂，葡萄糖氧化酶和过氧化物酶。在给予患者之后，胰岛素作为患者组织葡萄糖水平的函数从制剂中释放，其又将患者的血糖水平维持在最佳范围内。该制剂通常被称为“智能”制剂，因为其在特定时间根据患者的需要改变其胰岛素的释放速率。在优选的实施方案中，所述制剂被设计为在患者中注射后具有基础释放曲线随时间将胰岛素释放到全身循环中。在另一个实施方案中，所述制剂被设计成在患者注射后，例如常规人胰岛素释放曲线或餐时释放曲线，随着时间推移胰岛素进入体循环随着非基础释放曲线。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式